Skip to content
About Us
Science
Pipeline
News & Resources
About Us
Science
Pipeline
News & Resources
Contact Us
News
October 19, 2025
VT3989, Vivace Therapeutics’ Best-in-Class, Hippo Pathway-Targeting Therapy, Demonstrates Promising Antitumor Activity in Refractory Mesothelioma
Research and Publications
VIEW ALL
Publications and Presentations
March 7, 2013
The Hippo Pathway and Human Cancer
READ MORE
Publications and Presentations
November 5, 2015
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer
READ MORE
News
June 28, 2017
Vivace Therapeutics Comes out of Stealth with $40 Million to Turn Novel Biology into First-in-Class Cancer Therapeutics
READ MORE
